{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T22:48:38Z","timestamp":1791413318563,"version":"4.3.3"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Institute Pasteur of Shanghai"},{"DOI":"10.13039\/501100002367","name":"Chinese Academy of Sciences","doi-asserted-by":"publisher","award":["2014004"],"award-info":[{"award-number":["2014004"]}],"id":[{"id":"10.13039\/501100002367","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31400148"],"award-info":[{"award-number":["31400148"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002367","name":"Chinese Academy of Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002367","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1016\/j.antiviral.2015.11.003","type":"journal-article","created":{"date-parts":[[2015,11,14]],"date-time":"2015-11-14T08:30:30Z","timestamp":1447489830000},"page":"1-7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":65,"special_numbering":"C","title":["Teicoplanin inhibits Ebola pseudovirus infection in cell culture"],"prefix":"10.1016","volume":"125","author":[{"given":"Yizhuo","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guiming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianqian","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shilin","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Altmeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9607-7827","authenticated-orcid":false,"given":"Gang","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2015.11.003_bib1","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.2174\/1381612043382729","article-title":"Virus attachment and entry offer numerous targets for antiviral therapy","volume":"10","author":"Altmeyer","year":"2004","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.antiviral.2015.11.003_bib2","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd1468","article-title":"Drug repositioning: identifying and developing new uses for existing drugs. Nature reviews","volume":"3","author":"Ashburn","year":"2004","journal-title":"Drug Discov."},{"key":"10.1016\/j.antiviral.2015.11.003_bib3","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1056\/NEJMoa1404505","article-title":"Emergence of Zaire Ebola virus disease in Guinea","volume":"371","author":"Baize","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.antiviral.2015.11.003_bib4","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.antiviral.2006.03.005","article-title":"Inhibition of feline (FIPV) and human (SARS) coronavirus by semisynthetic derivatives of glycopeptide antibiotics","volume":"72","author":"Balzarini","year":"2006","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2015.11.003_bib5","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1021\/jm0300882","article-title":"Antiretroviral activity of semisynthetic derivatives of glycopeptide antibiotics","volume":"46","author":"Balzarini","year":"2003","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.antiviral.2015.11.003_bib6","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1016\/j.bmcl.2014.06.018","article-title":"Semisynthetic teicoplanin derivatives as new influenza virus binding inhibitors: synthesis and antiviral studies","volume":"24","author":"Bereczki","year":"2014","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.antiviral.2015.11.003_bib7","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/nature10348","article-title":"Ebola virus entry requires the cholesterol transporter Niemann-Pick C1","volume":"477","author":"Carette","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2015.11.003_bib8","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1126\/science.1110656","article-title":"Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection","volume":"308","author":"Chandran","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2015.11.003_bib9","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/448645a","article-title":"New uses for old drugs","volume":"448","author":"Chong","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2015.11.003_bib10","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/nature10380","article-title":"Small molecule inhibitors reveal Niemann-Pick C1 is essential for Ebola virus infection","volume":"477","author":"Cote","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2015.11.003_bib11","doi-asserted-by":"crossref","first-page":"e37244","DOI":"10.1371\/journal.pone.0037244","article-title":"An analogue of the antibiotic teicoplanin prevents flavivirus entry in\u00a0vitro","volume":"7","author":"De Burghgraeve","year":"2012","journal-title":"PloS One"},{"key":"10.1016\/j.antiviral.2015.11.003_bib12","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1089\/mdr.2004.10.346","article-title":"A\u00a0mouse peritonitis model for the study of glycopeptide efficacy in GISA infections","volume":"10","author":"Domenech","year":"2004","journal-title":"Microb. Drug Resist."},{"key":"10.1016\/j.antiviral.2015.11.003_bib13","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0140-6736(10)60667-8","article-title":"Ebola haemorrhagic fever","volume":"377","author":"Feldmann","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2015.11.003_bib14","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1093\/jac\/dku091","article-title":"The clinically approved drugs amiodarone, dronedarone and verapamil inhibit filovirus cell entry","volume":"69","author":"Gehring","year":"2014","journal-title":"J.\u00a0Antimicrob. Chemother."},{"key":"10.1016\/j.antiviral.2015.11.003_bib15","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1586\/14787210.2014.948848","article-title":"Reverse genetics systems as tools for the development of novel therapies against filoviruses","volume":"12","author":"Hoenen","year":"2014","journal-title":"Expert Rev. Anti-infective Ther."},{"key":"10.1016\/j.antiviral.2015.11.003_bib16","doi-asserted-by":"crossref","first-page":"190ra179","DOI":"10.1126\/scitranslmed.3005471","article-title":"FDA-approved selective estrogen receptor modulators inhibit Ebola virus infection","volume":"5","author":"Johansen","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.antiviral.2015.11.003_bib17","doi-asserted-by":"crossref","first-page":"290ra289","DOI":"10.1126\/scitranslmed.aaa5597","article-title":"A\u00a0screen of approved drugs and molecular probes identifies therapeutics with anti-Ebola virus activity","volume":"7","author":"Johansen","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.antiviral.2015.11.003_bib18","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1038\/emi.2014.88","article-title":"Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs","volume":"3","author":"Kouznetsova","year":"2014","journal-title":"Emerg. Microbes Infect."},{"key":"10.1016\/j.antiviral.2015.11.003_bib19","doi-asserted-by":"crossref","first-page":"e60579","DOI":"10.1371\/journal.pone.0060579","article-title":"A\u00a0systematic screen of FDA-approved drugs for inhibitors of biological threat agents","volume":"8","author":"Madrid","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.antiviral.2015.11.003_bib20","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1093\/jac\/dks217","article-title":"Teicoplanin therapy leading to a significant decrease in viral load in a patient with chronic hepatitis C","volume":"67","author":"Maieron","year":"2012","journal-title":"J.\u00a0Antimicrob. Chemother."},{"key":"10.1016\/j.antiviral.2015.11.003_bib21","doi-asserted-by":"crossref","first-page":"e1004731","DOI":"10.1371\/journal.ppat.1004731","article-title":"Ebola virus entry: a curious and complex series of events","volume":"11","author":"Moller-Tank","year":"2015","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2015.11.003_bib22","doi-asserted-by":"crossref","first-page":"e1001121","DOI":"10.1371\/journal.ppat.1001121","article-title":"Ebolavirus is internalized into host cells via macropinocytosis in a viral glycoprotein-dependent manner","volume":"6","author":"Nanbo","year":"2010","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2015.11.003_bib23","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1093\/jac\/dkr104","article-title":"Inhibition of hepatitis C virus replication by semi-synthetic derivatives of glycopeptide antibiotics","volume":"66","author":"Obeid","year":"2011","journal-title":"J.\u00a0Antimicrob. Chemother."},{"key":"10.1016\/j.antiviral.2015.11.003_bib24","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1093\/jac\/dkg147","article-title":"Teicoplanin therapeutic drug monitoring in critically ill patients: a retrospective study emphasizing the importance of a loading dose","volume":"51","author":"Pea","year":"2003","journal-title":"J.\u00a0Antimicrob. Chemother."},{"key":"10.1016\/j.antiviral.2015.11.003_bib25","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.antiviral.2006.04.008","article-title":"Polycyclic peptide and glycopeptide antibiotics and their derivatives as inhibitors of HIV entry","volume":"71","author":"Preobrazhenskaya","year":"2006","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2015.11.003_bib26","doi-asserted-by":"crossref","first-page":"e1001110","DOI":"10.1371\/journal.ppat.1001110","article-title":"Cellular entry of ebola virus involves uptake by a macropinocytosis-like mechanism and subsequent trafficking through early and late endosomes","volume":"6","author":"Saeed","year":"2010","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2015.11.003_bib27","article-title":"Amiodarone and metabolite MDEA inhibit Ebola virus infection by interfering with the viral entry process","volume":"73","author":"Salata","year":"2015","journal-title":"Pathogens Dis."},{"key":"10.1016\/j.antiviral.2015.11.003_bib28","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1007\/s11096-008-9251-2","article-title":"Vancomycin vs teicoplanin in the treatment of gram-positive infections: a pharmacoeconomic analysis in a Turkish university hospital","volume":"30","author":"Sancar","year":"2008","journal-title":"Pharm. World & Sci. PWS"},{"key":"10.1016\/j.antiviral.2015.11.003_bib29","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1093\/jac\/dkq266","article-title":"Analyses of teicoplanin concentrations from 1994 to 2006 from a UK assay service","volume":"65","author":"Tobin","year":"2010","journal-title":"J.\u00a0Antimicrob. Chemother."},{"key":"10.1016\/j.antiviral.2015.11.003_bib30","doi-asserted-by":"crossref","first-page":"167","DOI":"10.2165\/00003088-200039030-00001","article-title":"Clinical pharmacokinetics of teicoplanin","volume":"39","author":"Wilson","year":"2000","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.antiviral.2015.11.003_bib31","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1007\/s00134-003-1914-9","article-title":"Pharmacokinetics of teicoplanin in critically ill patients undergoing continuous hemodiafiltration","volume":"29","author":"Yagasaki","year":"2003","journal-title":"Intensive Care Med."},{"key":"10.1016\/j.antiviral.2015.11.003_bib32","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1177\/108705719900400206","article-title":"A\u00a0simple statistical parameter for use in evaluation and validation of high throughput screening assays","volume":"4","author":"Zhang","year":"1999","journal-title":"J.\u00a0Biomol. Screen."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354215300243?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354215300243?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,17]],"date-time":"2018-09-17T14:29:43Z","timestamp":1537194583000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354215300243"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":32,"alternative-id":["S0166354215300243"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2015.11.003","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Teicoplanin inhibits Ebola pseudovirus infection in cell culture","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2015.11.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}